title: [Multipurpose treatment of vaginal infections].
abstract: Untreated bacterial vaginosis is related with many complications for non-pregnant women in reproductive age, most common from them are vaginal discharge and postoperative infections. The aim of our investigation was to compare the effectiveness of two therapeutic regimes which consist in Macmiror/Macmiror Complex alone and in combination with Feminella Vagi C for treatment of bacterial vaginosis (BV) and/or mycotic infection. 117 non-pregnant women with symptoms of vaginal infection were prospectively enrolled into two groups according their treatment. First group consist 66 women treated with Macmiror tablets and vaginal capsules followed with local application of Feminella Vagi C, the second group consist 54 women treated with Macmiror tablets and vaginal capsules only. The impact of treatment on clinical symptoms was observed at the end of medication and 20 days after it. Microbiological testing was repeated 20 days after treatment. Over than 80% (78.6 divided by 86.7%) of the cases with vaginal infection (BV and mycotic one) were successfully treated with Macmiror/Macmiror Complex. Supplement treatment with Feminella Vagi C lead to higher percentage of clinically recovery (86.7% vs 84.6%), better microbiological cleaning (86.7% vs 82.1%) and longer effect of treatment. Used medication showed higher efficacy against BV than to fungal infection. According obtained results we may conclude that bacterial vaginosis was better treated with multipurpose treatment (Nifuratel, Nistatin and vit. C) than with Macmiror alone.
authors.forename: A
authors.initials: A
authors.lastname: Nikolov
authors.forename: A
authors.initials: A
authors.lastname: Masseva
authors.forename: E
authors.initials: E
authors.lastname: Shopova
authors.forename: S
authors.initials: S
authors.lastname: Georgiev
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D002175:Candida / Q000187:drug effects; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009545:Nifuratel / Q000627:therapeutic use*; D011446:Prospective Studies; D014621:Vagina / Q000187:drug effects / Q000382:microbiology*; D016585:Vaginosis, Bacterial / Q000188:drug therapy*; D014815:Vitamins / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D014815:Vitamins; D001205:Ascorbic Acid; D009545:Nifuratel